|A positive fecal occult blood test|
|Classification and external resources|
|eMedicine||radio/301 radio/302 emerg/381|
Gastrointestinal bleeding (GI bleed), also known as gastrointestinal hemorrhage, is all forms of bleeding in the gastrointestinal tract, from the mouth to the rectum. When there is significant blood loss over a short time, symptoms may include vomiting red blood, vomiting black blood, bloody stool, or black stool. Small amounts of bleeding over a long time may cause iron-deficiency anemia resulting in feeling tired or heart-related chest pain. Other symptoms may include abdominal pain, shortness of breath, pale skin, or passing out. Sometimes in those with small amounts of bleeding no symptoms may be present.
Bleeding is typically divided into two main types: upper gastrointestinal bleeding and lower gastrointestinal bleeding. Causes of upper GI bleeds include: peptic ulcer disease, esophageal varices due to liver cirrhosis and cancer, among others. Causes of lower GI bleeds include: hemorrhoids, cancer, and inflammatory bowel disease among others. Diagnosis typically begins with a medical history and physical examination, along with blood tests. Small amounts of bleeding may be detected by fecal occult blood test. Endoscopy of the lower and upper gastrointestinal track may locate the area of bleeding. Medical imaging may be useful in cases that are not clear.
Initial treatment focuses on resuscitation which may include intravenous fluids and blood transfusions. Often blood transfusions are not recommended unless the hemoglobin is less than 70 or 80 g/L. Treatment with proton pump inhibitors, octreotide, and antibiotics may be considered in certain cases. If other measures are not effective, an esophageal balloon may be attempted in those with persumed esophageal varices. Endoscopy of the esophagus, stomach, and duodenum or endoscopy of the large bowel are generally recommended within 24 hours and may allow treatment as well as diagnosis.
An upper GI bleed is more common than lower GI bleed. An upper GI bleed occurs in 50 to 150 per 100,000 adults per year. A lower GI bleed is estimated to occur in 20 to 30 per 100,000 per year. It results in about 300,000 hospital admissions a year in the United States. Risk of death from a GI bleed is between 5% and 30%. Risk of bleeding is more common in males and increases with age.
Signs and symptoms
Gastrointestinal bleeding can range from small non-visible amounts, which are only detected by laboratory testing, to massive bleeding where bright red blood is passed and shock develops. With bleeding that is rapid there may be syncope.
Blood that is digested may appear black rather than red, resulting in "coffee ground" vomit or tar colored stool called melena.
Gastrointestinal bleeding can be roughly divided into two clinical syndromes: upper gastrointestinal bleeding and lower gastrointestinal bleeding. About 2/3 of all GI bleeds are from upper sources and 1/3 from lower sources. Common causes of gastrointestinal bleeding include infections, cancers, vascular disorders, adverse effects of medications, and blood clotting disorders. Obscure gastrointestinal bleeding (OGIB) is when a source is unclear following investigation.
Upper gastrointestinal bleeding is from a source between the pharynx and the ligament of Treitz. An upper source is characterised by hematemesis (vomiting up blood) and melena (tarry stool containing altered blood). About half of cases are due to peptic ulcer disease. Esophageal inflammation and erosive disease are the next most common causes. In those with liver cirrhosis, 50–60% of bleeding is due to esophageal varices. Approximately half of those with peptic ulcers have an H. pylori infection. Other causes include gastric or duodenal ulcers, Mallory-Weiss tears, cancer, and angiodysplasia.
A number of medications are found to cause upper GI bleeds. NSAIDs or COX-2 inhibitors increase the risk about fourfold. SSRIs, corticosteroids, and anticoagulants may also increase the risk. The risk with dabigatran is 30% greater than that with warfarin.
Lower gastrointestinal bleeding is typically from the colon, rectum or anus. Common causes of lower gastrointestinal bleeding include hemorrhoids, cancer, angiodysplasia, ulcerative colitis, Crohn's disease, and aortoenteric fistula. It may be indicated by the passage of fresh red blood rectally, especially in the absence of bloody vomiting. Isolated melena may originate from anywhere between the stomach and the proximal colon.
A number of foods and medications can turn the stool either red or black. Bismuth found in many antacids may turn stools black as may activated charcoal. Blood from the vagina or urinary tract may also be confused with blood in the stool.
Diagnosis is often based on direct observation of blood in the stool or vomit. This can be confirmed with a fecal occult blood test. Differentiating between upper and lower bleeding in some cases can be difficult. The severity of an upper GI bleed can be judged based on the Blatchford score or Rockall score. The Rockall score is the more accurate of the two. As of 2008 there is no scoring system useful for lower GI bleeds.
Gastric aspiration and or lavage, where a tube is inserted into the stomach via the nose in an attempt to determine if there is blood in the stomach, if negative does not rule out an upper GI bleed but if positive is useful for ruling one in. Clots in the stool indicate a lower GI source while melana stools an upper one.
Recommended laboratory blood testing includes: cross matching blood, hemoglobin, hematocrit, platelets, coagulation time, and electrolytes. If the ratio of blood urea nitrogen to creatinine is greater than 30 the source is more likely from the upper GI tract.
A CT angiography is useful for determining the exact location of the bleeding within the gastrointestinal tract. Nuclear scintigraphy is a sensitive test for detecting occult gastrointestinal bleeding when direct imaging with upper and lower endoscopies are negative. Direct angiography allows for embolization of a bleeding source, but requires a bleeding rate faster than 1mL/minute.
In those with significant varices or cirrhosis nonselective β-blockers reduce the risk of future bleeding. With a target heart rate of 55 beats per minute they reduce the absolute risk of bleeding by 10%. Endoscopic band ligation (EBL) is also effective at improving outcomes. Either B-blockers or EBL are recommended as initial preventative measures. In those who have had a previous varcial bleed both treatments are recommended. With some evidence supporting the addition of isosorbide mononitrate. Testing for and treating those who are positive for H. pylori is recommended. Transjugular intrahepatic portosystemic shunting (TIPS) may be used to prevent bleeding in people who re-bleed despite other measures.
The initial focus is on resuscitation beginning with airway management and fluid resuscitation using either intravenous fluids and or blood. A number of medications may improve outcomes depending on the source of the bleeding.
Based on evidence from people with other health problems crystalloid and colloids are believed to be equivalent for peptic ulcer bleeding. Proton pump inhibitors (PPI) may reduce mortality in those with severe disease as well as the risk of re-bleeding and the need for surgery among this group. Oral and intravenous formulations may be equivalent; however, the evidence to support this is suboptimal. In those with less severe disease and where endoscopy is rapidly available, they are of less immediate clinical importance. There is tentative evidence of benefit for tranexamic acid which inhibits clot breakdown. Somatostatin and octreotide, while recommended for varicial bleeding, have not been found to be of general use for non variceal bleeds. After treatment of a high risk bleeding ulcer endoscopically giving a PPI once or a day rather than as an infusion appears to work just as well and is less expensive (the method may be either by mouth or intravenously).
For initial fluid replacement colloids or albumin is preferred in people with cirrhosis. Medications typically include octreotide or, if not available, vasopressin and nitroglycerin to reduce portal venous pressures. Terlipressin appears to be more effective than octreotide, but it is not available in many areas of the world. It is the only medication that has been shown to reduce mortality in acute variceal bleeding. This is in addition to endoscopic banding or sclerotherapy for the varices. If this is sufficient then beta blockers and nitrates may be used for the prevention of re-bleeding. If bleeding continues, balloon tamponade with a Sengstaken-Blakemore tube or Minnesota tube may be used in an attempt to mechanically compress the varices. This may then be followed by a transjugular intrahepatic portosystemic shunt. In those with cirrhosis, antibiotics decrease the chance of bleeding again, shorten the length of time spent in hospital, and decrease mortality. Octreotide reduces the need for blood transfusions and may decrease mortality. No trials of vitamin K have been conducted.
The evidence for benefit of blood transfusions in GI bleed is poor with some evidence finding harm. In those in shock O-negative packed red blood cells are recommended. If large amounts of pack red blood cells are used additional platelets and fresh frozen plasma (FFP) should be administered to prevent coagulopathies. In alcoholics FFP is suggested before confirmation of a coagulopathy due to presumed blood clotting problems. Evidence supports holding off on blood transfusions in those who have a hemoglobin greater than 7 to 8 g/dL and moderate bleeding, including in those with preexisting coronary artery disease.
If the INR is greater than 1.5 to 1.8 correction with fresh frozen plasma or prothrombin complex may decrease mortality. Evidence of a harm or benefit of recombinant activated factor VII in those with liver diseases and gastrointestinal bleeding is not determined. A massive transfusion protocol may be used, but there is a lack of evidence for this indication.
The benefits versus risks of placing a nasogastric tube in those with upper GI bleeding are not determined. Endoscopy within 24 hours is recommended, in addition to medical management. A number of endoscopic treatments may be used, including: epinephrine injection, band ligation, sclerotherapy, and fibrin glue depending on what is found. Prokinetic agents such as erythromycin before endocopy can decrease the amount of blood in the stomach and thus improve the operators view. They also decrease the amount of blood transfusions required. Early endoscopy decreases hospital and the amount of blood transfusions needed. A second endoscopy within a day is routinely recommended by some but by others only in specific situations. Proton pump inhibitors, if they have not been started earlier, are recommended in those in whom high risk signs for bleeding are found. High and low dose PPIs appear equivalent at this point. It is also recommended that people with high risk signs are kept in hospital for at least 72 hours. Those at low risk of re-bleeding may begin eating typically 24 hours following endoscopy. If other measures fail or are not available, esophageal balloon tamponade may be attempted. While there is a success rate up to 90%, there are some potentially significant complications including aspiration and esophageal perforation.
Colonoscopy is useful for the diagnosis and treatment of lower GI bleeding. A number of techniques may be employed including: clipping, cauterizing, and sclerotherapy. Preparation for colonoscopy takes a minimum of six hours which in those bleeding briskly may limit its applicability. Surgery, while rarely used to treat upper GI bleeds, is still commonly used to manage lower GI bleeds by cutting out the part of the intestines that is causing the problem. Angiographic embolization may be used for both upper and lower GI bleeds. Transjugular intrahepatic portosystemic shunting (TIPS) may also be considered.
Death in those with a GI bleed is more commonly due to other illnesses (some of which may have contributed to the bleed, such as cancer or cirrhosis), than the bleeding itself. Of those admitted to a hospital because of a GI bleed, death occurs in about 7%. Despite treatment, re-bleeding occurs in about 7–16% of those with upper GI bleeding. In those with esophageal varices, bleeding occurs in about 5–15% a year and if they have bled once, there is a higher risk of further bleeding within six weeks. Testing and treating H. pylori if found can prevent re-bleeding in those with peptic ulcers. The benefits versus risks of restarting blood thinners such as aspirin or warfarin and anti-inflammatories such as NSAIDs need to be carefully considered. If aspirin is needed for cardiovascular disease prevention, it is reasonable to restart it within seven days in combination with a PPI for those with nonvariceal upper GI bleeding.
Gastrointestinal bleeding from the upper tract occurs in 50 to 150 per 100,000 adults per year. It is more common than lower gastrointestinal bleeding which is estimated to occur at the rate of 20 to 30 per 100,000 per year. Risk of bleeding is more common in males, and increases with age.
- "Bleeding in the Digestive Tract". The National Institute of Diabetes and Digestive and Kidney Diseases. September 17, 2014. Retrieved 6 March 2015.
- Kim, BS; Li, BT; Engel, A; Samra, JS; Clarke, S; Norton, ID; Li, AE (15 November 2014). "Diagnosis of gastrointestinal bleeding: A practical guide for clinicians.". World journal of gastrointestinal pathophysiology. 5 (4): 467–78. doi:10.4291/wjgp.v5.i4.467. PMID 25400991.
- Westhoff, John (March 2004). "Gastrointestinal Bleeding: An Evidence-Based ED Approach To Risk Stratification". Emergency Medicine Practice. 6 (3).
- van Leerdam, ME (2008). "Epidemiology of acute upper gastrointestinal bleeding.". Best practice & research. Clinical gastroenterology. 22 (2): 209–24. doi:10.1016/j.bpg.2007.10.011. PMID 18346679.
- Jairath, V; Barkun, AN (October 2011). "The overall approach to the management of upper gastrointestinal bleeding". Gastrointestinal endoscopy clinics of North America. 21 (4): 657–70. doi:10.1016/j.giec.2011.07.001. PMID 21944416.
- Wang, J; Bao, YX; Bai, M; Zhang, YG; Xu, WD; Qi, XS (28 October 2013). "Restrictive vs liberal transfusion for upper gastrointestinal bleeding: a meta-analysis of randomized controlled trials.". World journal of gastroenterology : WJG. 19 (40): 6919–27. doi:10.3748/wjg.v19.i40.6919. PMID 24187470.
- Salpeter, SR; Buckley, JS; Chatterjee, S (February 2014). "Impact of more restrictive blood transfusion strategies on clinical outcomes: a meta-analysis and systematic review.". The American Journal of Medicine. 127 (2): 124–131.e3. doi:10.1016/j.amjmed.2013.09.017. PMID 24331453.
- Leontiadis, GI; Sreedharan, A; Dorward, S; Barton, P; Delaney, B; Howden, CW; Orhewere, M; Gisbert, J; Sharma, VK; Rostom, A; Moayyedi, P; Forman, D (December 2007). "Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding". Health technology assessment (Winchester, England). 11 (51): iii–iv, 1–164. doi:10.3310/hta11510. PMID 18021578.
- Cat, TB; Liu-DeRyke, X (September 2010). "Medical management of variceal hemorrhage". Critical care nursing clinics of North America. 22 (3): 381–93. doi:10.1016/j.ccell.2010.02.004. PMID 20691388.
- Chavez-Tapia, NC; Barrientos-Gutierrez, T; Tellez-Avila, F; Soares-Weiser, K; Mendez-Sanchez, N; Gluud, C; Uribe, M (September 2011). "Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding – an updated Cochrane review". Alimentary pharmacology & therapeutics. 34 (5): 509–18. doi:10.1111/j.1365-2036.2011.04746.x. PMID 21707680.
- Jairath, V; Hearnshaw, S; Brunskill, SJ; Doree, C; Hopewell, S; Hyde, C; Travis, S; Murphy, MF (2010-09-08). Jairath, Vipul, ed. "Red cell transfusion for the management of upper gastrointestinal haemorrhage". Cochrane database of systematic reviews (Online) (9): CD006613. doi:10.1002/14651858.CD006613.pub3. PMID 20824851.
- Prasad Kerlin, Meeta; Tokar, Jeffrey L. (6 August 2013). "Acute Gastrointestinal Bleeding". Annals of Internal Medicine. 159 (3): ITC2. doi:10.7326/0003-4819-159-3-201308060-01002.
- Srygley FD, Gerardo CJ, Tran T, Fisher DA (March 2012). "Does this patient have a severe upper gastrointestinal bleed?". JAMA. 307 (10): 1072–9. doi:10.1001/jama.2012.253. PMID 22416103.
- Palmer, K; Nairn, M; Guideline Development, Group (2008-10-10). "Management of acute gastrointestinal blood loss: summary of SIGN guidelines" (PDF). BMJ (Clinical research ed.). 337: a1832. doi:10.1136/bmj.a1832. PMID 18849311.
- Coleman, CI; Sobieraj, DM; Winkler, S; Cutting, P; Mediouni, M; Alikhanov, S; Kluger, J (January 2012). "Effect of pharmacological therapies for stroke prevention on major gastrointestinal bleeding in patients with atrial fibrillation.". International journal of clinical practice. 66 (1): 53–63. doi:10.1111/j.1742-1241.2011.02809.x. PMID 22093613.
- Palamidessi, N; Sinert, R; Falzon, L; Zehtabchi, S (February 2010). "Nasogastric aspiration and lavage in emergency department patients with hematochezia or melena without hematemesis.". Academic Emergency Medicine. 17 (2): 126–32. doi:10.1111/j.1553-2712.2009.00609.x. PMID 20370741.
- Wu, LM; Xu, JR; Yin, Y; Qu, XH (2010-08-21). "Usefulness of CT angiography in diagnosing acute gastrointestinal bleeding: a meta-analysis.". World journal of gastroenterology : WJG. 16 (31): 3957–63. doi:10.3748/wjg.v16.i31.3957. PMC 2923771. PMID 20712058.
- Barkun AN, Bardou M, Kuipers EJ, Sung J, Hunt RH, Martel M, Sinclair P (2010). "International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding". Ann. Intern. Med. 152 (2): 101–13. doi:10.7326/0003-4819-152-2-201001190-00009. PMID 20083829.
- Li, L; Yu, C; Li, Y (March 2011). "Endoscopic band ligation versus pharmacological therapy for variceal bleeding in cirrhosis: a meta-analysis". Canadian journal of gastroenterology = Journal canadien de gastroenterologie. 25 (3): 147–55. PMC 3076033. PMID 21499579.
- Tsoi, KK; Hirai, HW; Sung, JJ (Aug 5, 2013). "Meta-analysis: comparison of oral vs. intravenous proton pump inhibitors in patients with peptic ulcer bleeding.". Alimentary pharmacology & therapeutics. 38 (7): 721–8. doi:10.1111/apt.12441. PMID 23915096.
- Sreedharan, A; Martin, J; Leontiadis, GI; Dorward, S; Howden, CW; Forman, D; Moayyedi, P (2010-07-07). Sreedharan, Aravamuthan, ed. "Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding". Cochrane database of systematic reviews (Online) (7): CD005415. doi:10.1002/14651858.CD005415.pub3. PMID 20614440.
- Bennett, C; Klingenberg, SL; Langholz, E; Gluud, LL (21 November 2014). "Tranexamic acid for upper gastrointestinal bleeding.". The Cochrane database of systematic reviews. 11: CD006640. doi:10.1002/14651858.CD006640.pub3. PMID 25414987.
- Sachar, H; Vaidya, K; Laine, L (November 2014). "Intermittent vs continuous proton pump inhibitor therapy for high-risk bleeding ulcers: a systematic review and meta-analysis.". JAMA internal medicine. 174 (11): 1755–62. doi:10.1001/jamainternmed.2014.4056. PMC 4415726. PMID 25201154.
- Ioannou, G; Doust, J; Rockey, DC (2003). Ioannou, George N, ed. "Terlipressin for acute esophageal variceal hemorrhage". Cochrane database of systematic reviews (Online) (1): CD002147. doi:10.1002/14651858.CD002147. PMID 12535432.
- Gøtzsche, PC; Hróbjartsson, A (2008-07-16). Gøtzsche, Peter C, ed. "Somatostatin analogues for acute bleeding oesophageal varices". Cochrane database of systematic reviews (Online) (3): CD000193. doi:10.1002/14651858.CD000193.pub3. PMID 18677774.
- Wells, M; Chande, N; Adams, P; Beaton, M; Levstik, M; Boyce, E; Mrkobrada, M (June 2012). "Meta-analysis: vasoactive medications for the management of acute variceal bleeds". Alimentary pharmacology & therapeutics. 35 (11): 1267–78. doi:10.1111/j.1365-2036.2012.05088.x. PMID 22486630.
- Martí-Carvajal, AJ; Solà, I (9 June 2015). "Vitamin K for upper gastrointestinal bleeding in people with acute or chronic liver diseases.". The Cochrane database of systematic reviews. 6: CD004792. doi:10.1002/14651858.CD004792.pub5. PMID 26058964.
- Martí-Carvajal, AJ; Karakitsiou, DE; Salanti, G (2012-03-14). Martí-Carvajal, Arturo J, ed. "Human recombinant activated factor VII for upper gastrointestinal bleeding in patients with liver diseases". Cochrane database of systematic reviews (Online). 3: CD004887. doi:10.1002/14651858.CD004887.pub3. PMID 22419301.
- D'Amico, G; Pagliaro, L; Pietrosi, G; Tarantino, I (2010-03-17). d'Amico, Gennaro, ed. "Emergency sclerotherapy versus vasoactive drugs for bleeding oesophageal varices in cirrhotic patients". Cochrane database of systematic reviews (Online) (3): CD002233. doi:10.1002/14651858.CD002233.pub2. PMID 20238318.
- Bai, Y; Guo, JF; Li, ZS (July 2011). "Meta-analysis: erythromycin before endoscopy for acute upper gastrointestinal bleeding". Alimentary pharmacology & therapeutics. 34 (2): 166–71. doi:10.1111/j.1365-2036.2011.04708.x. PMID 21615438.
- Wu, LC; Cao, YF; Huang, JH; Liao, C; Gao, F (2010-05-28). "High-dose vs low-dose proton pump inhibitors for upper gastrointestinal bleeding: a meta-analysis". World journal of gastroenterology : WJG. 16 (20): 2558–65. doi:10.3748/wjg.v16.i20.2558. PMC 2877188. PMID 20503458.
- "Management of acute lower GI bleeding". University of Pennsylvania Health System (UPHS). Jan 2009. p. 6.